Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30971963 | 0.93 | DRD4 (0.43) | ALDH1A1L3MBTL1HRH3LTA4HDRD4 | |
| SCHEMBL30971911 | 0.85 | EGFR (0.47) | ALDH1A1L3MBTL1HRH3KDM4EDRD4 | |
| SCHEMBL30972154 | 0.81 | LTA4H (0.54) | LTA4H | |
| SCHEMBL30972142 | 0.80 | LTA4H (0.52) | HRH3LTA4H | |
| SCHEMBL30972116 | 0.78 | SIGMAR1 (0.41) | ALDH1A1L3MBTL1HRH3KDM4EDRD4 | |
| SCHEMBL30972091 | 0.78 | HRH3 (0.47) | L3MBTL1HRH3KDM4E | |
| SCHEMBL30972054 | 0.76 | HRH4 (0.51) | ALDH1A1HRH3LTA4HKDM4E | |
| SCHEMBL12911992 | 0.72 | CYP2D6 (0.43) | ALDH1A1HRH3KDM4E | |
| SCHEMBL30972139 | 0.72 | HRH3 (0.47) | HRH3LTA4H | |
| SCHEMBL30972035 | 0.72 | PRMT5 (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207263-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | ATM, CHEK2, CHEK1 | ALDH1A1 3923/4885L3MBTL1 2941/4885HRH3 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.